Maze Therapeutics, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.76 | $-0.76 | +0.0% | Beat |
| Q12026 FY2026 | $-0.43 | $-0.45 | -4.7% | Miss |
| Q42025 FY2025 | $-0.73 | $-0.65 | +11.0% | Beat |
Back to MAZE overview · MAZE holders · MAZE KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.